BeOne Medicines - ROA - Return on Assets 2014-2025 | ONC

BeOne Medicines - return on assets for the quarter ending March 31, 2025 was -6.73.

  • BeOne Medicines - average return on assets for 2024 was -12.29, a 44.49% decline from 2023.
  • BeOne Medicines - average return on assets for 2023 was -22.14, a 21.63% decline from 2022.
  • BeOne Medicines - average return on assets for 2022 was -28.25, a 21.92% decline from 2021.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

BeOne Medicines - ROA - Return on Assets 2014-2025 | ONC

  • BeOne Medicines - average return on assets for 2024 was -12.29, a 44.49% decline from 2023.
  • BeOne Medicines - average return on assets for 2023 was -22.14, a 21.63% decline from 2022.
  • BeOne Medicines - average return on assets for 2022 was -28.25, a 21.92% decline from 2021.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$46.7B
Daiichi Sankyo, - (DSNKY)$41.7B
Sandoz Group AG (SDZNY)$24.6B
Summit Therapeutics (SMMT)$18.6B
Merck (MKKGY)$17.2B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.3B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.6B
Corcept Therapeutics (CORT)$7.6B
Madrigal Pharmaceuticals (MDGL)$7B
Grifols, S.A (GRFS)$6.7B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.1B
Crinetics Pharmaceuticals (CRNX)$3B
Hypermarcas (HYPMY)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B
Endo (NDOI)$1.6B